Skip to main content

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome Cover

.blurhash-client-img { display: none !important; }

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Romanian Journal of Internal Medicine

Volume 60 (2022): Issue 1 (March 2022)

By: Hasan H. Yeter, Ulver Derici, Turgay Arinsoy, Kadriye Altok, Yasemin Erten and Galip Guz

Open Access

|Mar 2022

Articles in this issue

DOI: https://doi.org/10.2478/rjim-2021-0034 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749

Journal RSS Feed

Language: English

Page range: 56 - 65

Submitted on: Jun 22, 2021

|

Published on: Mar 17, 2022

Published by: N.G. Lupu Internal Medicine Foundation

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

atypical hemolytic uremic syndrome,

therapeutic plasma exchange,

discontinuation,

Related subjects:

Clinical medicine,

Internal medicine,

Internal medicine, other,

Gastroenterology,

© 2022 Hasan H. Yeter, Ulver Derici, Turgay Arinsoy, Kadriye Altok, Yasemin Erten, Galip Guz, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 60 (2022): Issue 1 (March 2022)

Previous article